INS and metabolic syndrome: Treatment with L-4F is shown to increase both HO-1 and adiponectin levels in vitro and in vivo [2, 15] while decreasing superoxide (Figure 3(a)), further supporting the idea that L-4F improves the phenotype in the metabolic syndrome mouse model through an increase in insulin sensitivity and glucose tolerance.